AptaBio Therapeutics Inc. (KOSDAQ:293780)

South Korea flag South Korea · Delayed Price · Currency is KRW
7,460.00
-20.00 (-0.27%)
Feb 27, 2026, 3:30 PM KST
Market Cap209.58B +16.2%
Revenue (ttm)3.44B +18.4%
Net Income-20.23B
EPS-804.26
Shares Out28.09M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume151,558
Average Volume185,441
Open7,480.00
Previous Close7,480.00
Day's Range7,330.00 - 7,580.00
52-Week Range6,610.00 - 11,960.00
Beta1.04
RSI36.93
Earnings Daten/a

About AptaBio Therapeutics

AptaBio Therapeutics Inc., a biopharmaceutical company, develops platform based drugs for intractable diseases. Its platforms include Oxidative stress modulation platform for developing therapeutic agents for diabetes complications, vascular diseases, neurodegenerative diseases, and intractable cancers by controlling oxidative stress; Cancer-associated fibroblast control platform for developing new anticancer drugs for intractable cancer; and Aptamer-drug conjugate platform for developing intractable anticancer drugs with high unmet medical nee... [Read more]

Sector Healthcare
Founded 2009
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 293780
Full Company Profile

Financial Performance

In 2024, AptaBio Therapeutics's revenue was 3.36 billion, an increase of 937.76% compared to the previous year's 323.87 million. Losses were -29.38 billion, 147.6% more than in 2023.

Financial Statements